These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9136071)

  • 1. Statistical modeling of dose-response relationships in clinical trials--a case study.
    Holmgren EB; Koch GG
    J Biopharm Stat; 1997 May; 7(2):301-11. PubMed ID: 9136071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials.
    Wei ZH; Wang H; Chen XY; Wang BS; Rong ZX; Wang BS; Su BH; Chen HZ
    Eur J Clin Nutr; 2009 Jul; 63(7):821-7. PubMed ID: 18985059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sense and nonsense of regression modeling for increasing precision of clinical trials.
    Cleophas TJ
    Clin Pharmacol Ther; 2003 Sep; 74(3):295-7. PubMed ID: 12966373
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.
    Berry DA; Berry SM; McKellar J; Pearson TA
    Am Heart J; 2003 Jun; 145(6):1036-45. PubMed ID: 12796760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
    MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
    [No Abstract]   [Full Text] [Related]  

  • 9. [Preventing infarct by lowering LDL. Is 100 the upper limit for every diabetic patient?].
    MMW Fortschr Med; 2003 Sep; 145(38):60. PubMed ID: 14603687
    [No Abstract]   [Full Text] [Related]  

  • 10. Adaptive modelling of dose-response relationships using smoothing splines.
    Kirby S; Colman P; Morris M
    Pharm Stat; 2009; 8(4):346-55. PubMed ID: 19205006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].
    Nissen S
    MMW Fortschr Med; 2004 Mar; 146(13):65. PubMed ID: 15219143
    [No Abstract]   [Full Text] [Related]  

  • 12. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1329-30. PubMed ID: 15297284
    [No Abstract]   [Full Text] [Related]  

  • 13. A Dunnett-Bonferroni-based parallel gatekeeping procedure for dose-response clinical trials with multiple endpoints.
    Xu H; Nuamah I; Liu J; Lim P; Sampson A
    Pharm Stat; 2009; 8(4):301-16. PubMed ID: 19065544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
    Kinlay S
    J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A random-effects mixture model for classifying treatment response in longitudinal clinical trials.
    Xu W; Hedeker D
    J Biopharm Stat; 2001 Nov; 11(4):253-73. PubMed ID: 12018779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Low LDL cholesterol, statins, and brain hemorrhage: should we worry?
    Vos E; de Groot P
    Neurology; 2007 Oct; 69(14):1469; author reply 1470. PubMed ID: 17909161
    [No Abstract]   [Full Text] [Related]  

  • 17. [Statins plus cholesterol resorption inhibitor. LDL goal values attainable].
    MMW Fortschr Med; 2002 Sep; 144(38):56. PubMed ID: 12395708
    [No Abstract]   [Full Text] [Related]  

  • 18. Bayesian modelling of multivariate quantitative traits using seemingly unrelated regressions.
    Verzilli CJ; Stallard N; Whittaker JC
    Genet Epidemiol; 2005 May; 28(4):313-25. PubMed ID: 15789447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal design for dose response using beta distributed responses.
    Wu Y; Fedorov VV; Propert KJ
    J Biopharm Stat; 2005; 15(5):753-71. PubMed ID: 16078383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.